This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk10: Hello and welcome to the Outlook Therapeutics inaugural quarterly update conference call and webcast. As a brief reminder, all participants are currently in a listen-only mode. If anyone requires operator assistance during the event, please press star zero on your telephone keypad. Following the presentation, there will be a question and answer session. Note that this webcast is being recorded at the company's request and a replay will be made available on the company's website following the end of the event. It is now my pleasure to turn the call over to Janine Thomas of Investor Relations.
spk01: Thank you, Daryl. At this time, I would like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations, or future projections. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws and are based on Outlook Therapeutics' current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the Outlook Therapeutics Annual Report on Form 10-K for the fiscal year ended September 30, 2023, and in other reports and files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully. Additionally, certain information contained in this webcast relates to or is based on studies, publications, surveys, and other data obtained from third-party sources and the company's own estimates and research. While the company believes that these third-party sources to be reliable as of the date of this presentation, that has not independently verified and makes no representation as to the adequacy, fairness, accuracy, or completeness of that, or that any independent source has verified any information that comes from third-party sources. During the call, the company will discuss non-GAAP financial measures, which are not prepared in accordance with U.S. generally accepted accounting principles. Definition of these non-GAAP financial measures, along with reconciliations at the most directly comparable GAAP financial measures, are included in our second quarter earnings release, which has been furnished to the SEC and is available on the company's website at ir.outlooktherapeutics.com. Joining us on the call from Outlook Therapeutics leadership team are Russell Trenary, President and Chief Executive Officer, and Lawrence Kenyon, Chief Financial Officer of Outlook Therapeutics. I would now like to turn the call over to Russ. Please proceed.
spk05: Thank you, Janine. And thank you to everyone joining us for the company's first earnings call and webcast. To begin, I feel it's important to restate our mission and what we are working to accomplish. Our goal is to enhance the standard of care in the retina anti-VEGF space by achieving the first approval for an ophthalmic formulation of Bevacizumab for the treatment of retina diseases in the United States and Europe. Accomplishing this with our product candidate, ONS 5010, could provide people afflicted with wet AMD an effective form of bevacizumab that meets the FDA and EU's stringent efficacy, safety, and quality standards. So this is not a distant, long-term goal for us. Following our recent positive opinion from the CHMP, we believe we are on the cusp of receiving a potential approval for ONS 5010 in Europe, which we expect this quarter, calendar Q2 2024, and we are making significant potential progress for approval in the United States as well. We also submitted our MAA, or Marketing Authorization Application, to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom. So in Europe, which represents a significant market opportunity for us, we're making tremendous progress and expect to be in a position to launch in the UK and in the EU in the first quarter of calendar 2025. Regarding the United States, we've been actively engaged with the FDA and will continue to do so leading up to our expected BLA resubmission. As part of these interactions, earlier this year we reached agreement with the FDA on a special protocol assessment, or SPA, for NORS 8, our ongoing 90-day non-inferiority study for which we inspect top line data in the fourth calendar quarter of this year, 2024. Shortly thereafter, our goal is to resubmit our BLA by the end of this calendar year. Turning to our financial picture, we believe we're strongly positioned. We recently closed a private placement with gross proceeds of up to $172 million. Of that, $65 million is in cash from the issuance and sale of common stock, which are accompanied by warrants to purchase shares of common stock, and that's already been received, plus an additional $107 million, which will be available upon the full cash exercise of the warrants. Assuming the full cash exercise of the warrants, we expect our accessible capital to fund the business through our potential approval and commercial launch in parts of Europe and through the completion of NorthSafe, plus a potential FDA approval and the subsequent launch in the United States. Of note, this financing included participation by a couple longtime supporters of the company, as well as a good number of additional fundamental healthcare-focused institutional investors. Larry will speak to this a little bit later in the call. I'd like to drill down a little bit more on our activities in the EU and UK. In the EU, we expect potential approval this quarter, and in the UK, we expect potential approval in the third quarter of calendar 2024, this year, with initial launches in the first quarter of calendar 2025. As we await potential approval in the EU, We're working with Sincora, formerly AmerisourceBergen, and their EU units to leverage their existing infrastructure and expertise to support launching ONS 5010 ourselves in Europe. I'd like to emphasize the importance of the opportunity in Europe, which is the second largest market for wet AMD globally. So not only will it potentially be where we start generating revenue in the first half of calendar 2025, but it will validate all the hard work we've done to date. First, it will validate our entire development program for ONS 5010, including the positive safety and efficacy data we generated in our pivotal NORS II trial, plus the learnings from NORS I, which informed our NORS II study design. Also, the additional patient exposures established in NORS III to meet FDA's required safety population size And it also puts an exclamation point on the entirety and the quality of our CMC work. Now turning to the U.S. We reached agreement with the FDA on our SPA and launched NORSATE, a three-month non-inferiority study with an eight-week efficacy endpoint. This study has progressed as planned, and we've already enrolled over 30% of the patients to date. We continue to expect to complete enrollment in the third quarter of this year as planned and be in a position to report top line data and resubmit our BLA in the fourth quarter of this year. Additionally, we're meeting with the FDA in Type C and Type D meetings in order to discuss the resolution of the C and C questions and comments that were received in the CRL last year. The Type C and D meetings are not required by FDA. These interactions are at our request, with the goal of doing everything in our power to address the FDA's CMC questions while streamlining the process for resubmitting our BLA. Importantly, we anticipate these open CMC items will be resolved in calendar Q2 and Q3 this year, 2024, in advance of the NORSATE data readout. I'd also like to reiterate that the CMC comments from the CRL do not have any impact on our current supply of ONS 5010. We're working with reputable manufacturers that are actively using ONS 5010 from these partners in the ongoing NORSATE study. We believe that if successful, these activities will be sufficient for potential approval in the United States in calendar 2025. And now, It's my pleasure to turn the call over to Larry Kenyon, our Chief Financial Officer.
spk03: Larry? Thank you, Russ. Good morning, everyone. To begin, I'm very pleased to report that for the first time in the history of Outlook Therapeutics, we have secured access to the capital to potentially fully execute on our goal to receive approval for and launch ONS 5010. While we still are waiting to receive the EU approval and complete for our VLA resubmission at the end of calendar 2024, We believe our successful pipe financing that closed in March and April provides the necessary cash resources to support launches in the U.S. and Europe. The Outlook Therapeutics team is grateful to GMS Ventures and Investments and Syntone for their continued support of our mission. We also welcome the significant new institutional health care funds that see the opportunity here to upgrade the standard of care for treating wet AMD in patients around the world. Our current cash position, when combined with the expected proceeds from the full exercise of warrants to purchase shares of common stock, subject to meeting the requirements for calling the warrants, should be sufficient to support our operations through calendar 2025. Moving on to our financial results for the second fiscal quarter of 2024, I want to note that going forward, we are and will be using non-GAAP-adjusted results to eliminate the noise caused by the non-cash quarterly fair value changes for our warrants and convertible notes that are reflected in the P&L and balance sheet. For the second fiscal quarter of 2024, I can report that we remain on track with our spending plan for the year. The increase in our R&D expenses during the fiscal second quarter versus Q1 of this year came in as expected as we began recruiting and initiating clinical trial sites for NORS 8 and also began enrolling patients. Previously, we had reported that we estimated we could complete NORS 8 for a total of $30 million, with most of these expenses to be incurred during the first three calendar quarters of 2024. We have not changed our estimates for North 8 and expect that overall R&D expenses will continue to run at these levels for the next two quarters. Fiscal Q2 G&A expenses were in line with Fiscal Q1, and we also expect this to continue for the next two fiscal quarters as we prep for the anticipated approvals in the EU and UK and plan for a launch there in early calendar 2025. I will now turn the call back over to the operator for the Q&A portion.
spk10: Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. The confirmation tone will indicate your line is in the question queue. You may press star 2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star key. One moment, please, while we poll for your question. Our first questions come from the line of Julian Harrison with BTIG. Please proceed with your questions.
spk07: Hi, good morning. Congrats on all the progress, and thank you for taking my questions. First, I'm wondering if there are any preceding data sets in particular you would highlight as being especially de-risking for Norse 8. And second, great to see the positive CHMP opinion back in March. I'm curious how large the Europe market opportunity for ONAS 5010 is relative to the U.S., and Sorry if I missed it. Is this something you could pursue alone or is a partner there the most likely path forward?
spk05: Thanks, Julian. I'll go ahead and take the market size first. Europe is a really super looking opportunity for us. If you look at the number of injections for off-label Bevacizumab in Europe, they're quite similar to the United States. They get close to about 3 million injections per year. There's a little bit of price compression in Europe compared to the United States, but it still looks like a very enticing opportunity, and we look forward to capitalizing on that. We are planning to work in conjunction with CENTCORA, formerly Amerisource Bergen, who have units who are fully capable of not only conducting all of the 3PL activities, but also They have great HTA payer connectivity. They've got pharmacovigilance, which we'll be utilizing. In the U.S., they've got GPO contracting services. They've got medical literature distribution. And we'll be utilizing all of that functionality in both the United States and in Europe. And then what we'll be doing is we'll be the customer-facing arm in both markets where it'll be, you know, our sales reps and MSLs that we hire are So it will be an outlook launch. Turning back to the data set that you mentioned that might portend the relative success of NORS8 and why we are so confident in that, that's a great question because in our NORS2 pivotal trial, which had spectacular data associated with that year-long trial, There's a detail in there that not everybody remembers, and that is that the first 90 days of our NORS II pivotal trial had an identical dosing regimen to our current NORS VIII trial. So in other words, in both NORS VIII, the current trial, as well as NORS II, our very successful initial pivotal trial, there was dosing of either ONS 5010 or ranabizumab or lucentis at day zero, day 30, and day 60. And so when we go back and we look at those data during that period of time in the NORS II trial, we see non-inferiority between the ONS 5010 line and the lucentis line. So in terms of best corrected visual acuity, which is the primary endpoint for NORS VIII. So because there was such a small difference in letters gained between Lucentis and ONS 5010 in NORS II during that day zero, day 30, day 60 timeframe, we certainly do expect to see the same thing duplicated in NORS VIII.
spk10: Julian, did you have a follow-up question?
spk07: That was it for me. Very helpful. Thank you very much. Great. Thanks, Julie.
spk10: Thank you. Our next questions come from the line of Eddie Hickman with Guggenheim Securities. Please proceed with your questions.
spk04: Hi. Good morning. Congrats on all the progress. Just a couple questions from me. Can you talk about how many sites you currently have enrolling patients and what the goal and sort of cadence of that site coming online will be? And then if you could remind us of your pricing discussions with both commercial and government plans. I know the landscape will be a little bit different next year than it was last year, given some of the new approvals. So I'm just sort of curious if you'd update us on those discussions. Thanks.
spk05: Yeah, so I think this is the first month, Eddie, that we have 60 sites or more that are enrolling patients. And we had almost that same number in April. So we kind of look at April as the first month month where we were kind of full bore. I think we got one more site that still needs to be activated, but we're pretty much at full strength right now. So for us to have just reached mostly full strength in April, be in full strength in May, and with March having been a partially full strength month, to already have 30% of the patients enrolled is really encouraging. The sites are very happy about the study design, the ease with which recruiting is. You know, patients get either a product that the doctors have been using for several decades or ONS 5010, so they feel like it's a win-win, no matter which arm the patient gets randomized into. So it's a very encouraging start, and we're going to try to keep the pedal to the metal and get this thing enrolled inside the third quarter of this year. In terms of pricing, we really like how it's shaping up because I think if you looked over last year and the year before, you started to see some, relatively speaking, some price declines among the major brands in the United States and in Europe. And now with the launches of some of the super high-priced brands, That ASP for the anti-VEGF space, we expect to go up. And I think the important thing for people to understand about this space is the following. It's always been a two-segment market. There's always been a low-cost bevacizumab segment, albeit one that was off-label, didn't meet ophthalmic standards, didn't really have the type of quality that the doctors were necessarily looking for, but It was oftentimes mandated by payers to start with that before moving on to something that was multiples more expensive than the off-label. So that part of the market, that almost 50% of the injection has always been there and it's been untouchable until we're going to come along. The rest of the other 50% has been the battleground for the biosimilars, the major brands, and now the the new launches that have come out from the other companies. The new launches from the other companies are driving the ASP up. You know, they're switching a lot of their own customers to their higher-priced brand, or they're taking market share from others, from their product, into a higher price. So we like how the pricing is working for us, and we think the paradigm of having a two-segment market will continue. There will still be a lower-cost evasizumab market, It's about half of the injections and then the other half being the battleground for everybody else. Is that everything you were looking for, Eddie?
spk04: Yeah, no, very helpful. And is this only a three-month study? And sort of what are these doctors saying about what they would do to those patients after they're finished with three months? You know, they obviously wouldn't want to go back to like a non-branded version. So I'm just sort of curious like how you're thinking about, you know, recruiting those docs for a future launch.
spk05: Yeah, well, I think the best way to recruit those doctors for a future launch is having them part of the study and then see what kind of clinical results emerge from our study, which, again, we expect to show non-inferiority to Lucentis. So that's, you know, I think that's setting up for us rather nicely. But you are correct. It is a 90-day study. The injections will occur immediately. There are three injections that will occur at day zero, the day of randomization, and then day 30, and then day 60, and the patient will exit the study at day 90. So the primary endpoint is at day 60, and that'll be best corrected visual acuity, and we'll be looking for a non-inferiority margin of three and a half letters to Lucentis, which was, again, achieved in NORS II, although that was not a pre-specified statistic for that particular study. It wasn't necessary for the outcomes of that study. So we expect this one to show non-inferiority again. And then after the patient exits the study, I think it's really up to the doctors and the payers to determine what happens next and what therapy they move them to next.
spk10: Thank you. Our next question has come from the line of Douglas Schauer with HC Wainwright. Please proceed with your questions.
spk09: Hi, good morning. Thanks for taking the questions. Just, Russ, I just want to clarify a couple things. Was the 30% enrollment as of today, or was that as of March 31st?
spk05: That was as of yesterday.
spk09: And what was the number? So you said there's 60 sites up now. What was the number of sites? the progression through, say, in March and April?
spk05: Probably in March, we probably had about half of the sites enrolled at that point. And then in April, we pretty much got the rest of them enrolled either by the end of March or at the beginning of April. So we kind of felt that April was sort of a full-strength month for us, and of course, May will be also.
spk09: Okay, great. Thanks. And then I'm just curious, have you, you know, given the progress in the wet AMD market as well as the funding, you know, what's the latest thinking in terms of DME and the bravo indication? Thank you.
spk05: Yeah, it's a great question, Doug. We do have in our pipeline studies for DME and BRPL planned. You know, it's interesting today that DME and BRBO are also treated with off-label Avastin, so we don't know how that'll develop necessarily in the future. But for us, we want to make sure that our sales organization is always in the safest position to promote across the full breadth of the capabilities of ONS 5010, which we believe will include DME and BRBO, but we're going to have to do those studies to prove that. So, Initially, our first approval will be in wet AMD, which, as you know, Doug, is, you know, up to about 70% of the market in that anti-veg space.
spk09: Yeah, absolutely. And just given, you know, some of the maybe the changes within the FDA division, do you think it's necessary to go back and revisit sort of what would be needed to get those approvals? And what I mean by it is obviously with North 8, you got a fairly – I would argue, favorable study than to align with you on a fairly favorable study, certainly in duration. Do you think something like an eight-week endpoint in DME or DRVO would be sufficient? Thank you.
spk05: Yeah, I think we are in discussions with FDA pretty constantly now. Our relationship has really grown to an excellent level, and we do plan on on addressing with FDA. Given the real success of NORS II and what our expected success will be on NORS VIII, given that platform as well as the safety exposures that were generated in NORS III, we will want to ensure that we in FDA have a pristine understanding of of what all the requirements will be for a DME and a BRBO study. And we'll evaluate continuing the game plan that we've used in the past to use type A meetings and potentially SPA approvals to ensure that we have the air on the same page regarding those studies.
spk09: Okay, great. I'll jump back out into it here.
spk10: Thank you. Our next questions come from the line of Tim Chang with Capital One. Please proceed with your questions.
spk08: Hi, thanks. You know, as you guys prepare for the launch in Europe, can you talk a little bit about, you know, what some of your contract manufacturers, your partnerships with those, your packaging partners, you know, what they're doing to prepare for the launches in Europe and also in the U.S. next year?
spk05: Yeah, I mean, well, we've got inventory now. So we've already been through the process of developing and producing the drug substance out of Fujifilm Diacinth in College Station, Texas, as well as the fill-and-finish operation that occurs with Ajinomoto Biopharm in San Diego, California. And then our packaging takes place and labeling and serialization takes place with PCI. So we've got inventory sitting on the shelf. We are going to have to wait for final approval and final labeling before we get that product into final packaging and labeling. So we've got the beginning of the pipeline stoked, and we just need to get that product into final packaging and labeling. And then from there on, it's just really just continuing to place orders with our manufacturers and be in a position to have enough to ship to both Europe as well as the United States.
spk08: Okay, super. Is there anything else that you think you need to remediate or update leading up to your meeting with the FDA, the Type A meeting?
spk05: We actually don't have any more Type A meetings planned with them on this particular product. We are conducting Type C and Type D meetings, but those are either one or a number of agenda items pertaining to CMC that we meet with FDA to go through with them the studies that we've conducted, the analysis that we've done, the statistics that we have, and the data pertaining to answering all of the questions that they had in the CRL. We've already had one of those meetings. We've got another one on the calendar schedule. We've had a very successful run with them, and I think what it What it allows us to do is, first of all, ensure that we and the FDA are hearing each other, and so far so good, and ensure that the data we have produced to answer the CMC questions are being looked at by the FDA, and to ensure that by the time we resubmit this BLA, they will then be seeing our CMC data for the third time. The initial application, then again in the type C and D meetings, and in the resubmission. So we believe that this is not only streamlines our submission process, but also streamlines the review process for FDA. So we've had a, this came at the suggestion of the FDA. It wasn't a requirement, but in our first type A meeting with them last year, they made note of the fact that they thought it might be a good idea. And so we've, we have been following orders. And I think that our relationship with the FDA has grown to a very healthy place by engaging with them relatively constantly during this process.
spk08: Okay. That's very helpful. Thanks, Russell. You bet.
spk10: Thank you. Our next questions come from the line of Douglas Hau with HC Wainwright. Please proceed with your questions. Douglas, could you check if you're on mute, please?
spk09: Oh, sorry. Thanks for taking questions again. Just to clarify, Russ, your comments earlier about how you're thinking about commercialization in Europe. Is this the plan now to launch with an ONS field force, or are you still contemplating potential partnerships with companies that have the field presence already? Thank you.
spk05: Yeah, thanks, Doug. Yeah, we're We're focused on executing the things that we can do ourselves. We will always entertain conversations with other partners, and if we ever come to a determination that they can do it better than we can, our job is to maximize shareholder value and ensure that we do the best job of creating a great top line and a great bottom line on behalf of our shareholders. Right now we're focused on what we can do, but we're not closed-minded, and we will listen to people who might want to feel like they can be helpful to us. Okay, thank you.
spk10: Thank you. Our next questions come from the line of Kemp Dolliver with Brookline Capital Markets. Please proceed with your questions.
spk11: Great, thank you. How does the EU differ from from the U.S. in the context of how the health plans will position your product versus all the other options? Because in the U.S., they're pretty much going to have you at the pole position initially until patients fail therapy and then move on to something else. Focusing on the EU5, how do they differ, if at all?
spk05: Yeah, they not only differ in five different ways, but even within countries. There are regional differences within the countries. In the U.K., for example, there is just a trace of off-label betacizumab. So I think it gives us an opportunity to establish ourselves as a great brand that is priced according to what doctors and payers want. which is the same strategy that we used in the United States. You know, unlike a lot of, probably unlike everybody who came before us in the United States, you know, the pricing strategy that we took was to ensure that doctors and payers understood our value proposition. Of course, they understand what the rest of the landscape looks like. They understand how much switching goes on. from off-label Bevacizumab to a brand. And now they understand why some of that switching is going on. And a lot of that is due to the inability of off-label Bevacizumab to meet the characteristics that would be required for a regulatory approval in ophthalmology. So in educating the audience on that, then the last question really was, how would you like us to price this? What do you think is fair? And be mindful of the fact that even though you start with an off-label price, you don't finish there a lot of the time. So your average price per injection per patient over a three-year period of time, switching into account, is a lot closer to $1,000 per injection than it is to what you're paying for off-label at $100 per injection or less. So that same paradigm, generally speaking, exists throughout Europe as well. In most markets, there is off-label. In most markets, there is a group, a cabal of high-priced brands that are out there. And so although the price is compressed a bit from the United States, you know, the United States, the brands are priced, their wholesale acquisition costs in some cases exceed $2,600 per injection. There are also high prices in Europe, but just not that high. So we see the paradigm change. in Europe in terms of number of injections being very similar to the United States, and the thought process around what payers and doctors are looking for to be pretty similar to the U.S., albeit with a little bit of price compression.
spk11: Okay. Russ, just to be clear, so the practice in those countries where there is activity is is they will start a patient on the off-label Avastin and then switch if necessary.
spk05: Yes, some of that behavior exists in Europe like it does in the United States. And look, let's be clear. Some patients are high responders, and there are some patients who even with off-label that does not meet, ophthalmic requirements for approval in the EU and the United States can sometimes take a patient from start to finish. But if you look at the entire cohort and all of the patients who start on off-label, there's so much switching going on that it drives the price way higher than people might have expected in both the United States as well as in Europe because they don't necessarily continue to respond to an off-label bevacizumab that does not meet the requirements for a regulatory approval. So we believe that by bringing ours on, which meets all the same requirements for utter lack of particulates, or the right drug protein concentration, or approved packaging, the right pH levels, the right endotox levels, specifications for osmolarity. We check all of those boxes that are not or cannot be met by an off-label product that ends up being removed from its original packaging and aliquoted and refiltered back into small volume syringes and vials. There are things that happen to the molecule during that process that are untoward and can be retard the amount of drug protein concentration that is then left available in those small volume syringes and vials. So we believe that by bringing regulatory approved quality, that's why we get regulatory, why we expect regulatory approval with our safety and efficacy data.
spk11: Thank you very much.
spk10: Thank you. Our next questions come from the line of Ed Wu with Ascendant Capital Markets. Please proceed with your questions.
spk06: Yeah, congratulations on the progress. My question is on the manufacturing and supply for Europe. Do you anticipate having to move production there as you commercialize the product there?
spk05: We don't need to initially, but we'll always be looking to maximize production our global footprint as it pertains to that. So we will look at, and frankly, our partners also have facilities that are located in Europe. So as we look to the future, we'll balance the needs of Europe and the United States and the costs associated with landing the product in Europe from either our current locations or other locations that we'll look at in the future. But for now, we're good to go.
spk06: Great. Well, thanks for answering my questions, and I wish you guys good luck. Thank you. Great.
spk05: Thanks so much.
spk10: Thank you. Our next questions come from the line of Daniil Gitalin with Chardin. Please proceed with your questions.
spk02: Good morning, guys. Thank you for taking the question, and congrats on the progress. Can you talk about the timing for the type C and D meetings for the CMC questions, and do you anticipate to provide a separate communication when the issues have been fully addressed?
spk05: Oh, we expect all of the type C and type D meetings to be handled within the second and third quarter of this year. We won't be giving updates because, you know, when you go into those meetings, that'd be like giving you an update on my staff meeting. You know, you go into these type C and type D meetings, they're very focused, they're very technically oriented. But I can say that we know for a fact, having already been through one of these that FDA has been pleased with our approach and pleased with the data that we produced and are not unhappy that they're getting a look at this prior to us resubmitting. So our suspicion that this would be helpful to them and would aid them in the review process I think has been validated.
spk02: Okay, thank you. And one more quick question. Initially, will your product be supplied in wireless, and are you still conducting work for our pre-filled syringes?
spk05: Yes, we are doing work. Our pre-filled syringe project does continue to progress. We do have one more arm of a study, our NORS 7 study. We've already enrolled the first arm, which would be the control arm, we will now, once we get through the stability work that's required for the syringe, we will enroll at second arm for NOR7. We do not expect to apply for approval for pre-filled syringe until we have final approval from FDA. As you probably know, we're dealing not only with the pharmaceutical and biologics group, but also with the medical device group at FDA. So we get You get to talk with those folks twice on this one. And like the other companies who have learned the hard way, we're going to learn the smart way and make sure that we get our approval under our belt before we apply for the pre-filled syringe.
spk02: Got it. All right. Thank you for taking the questions.
spk10: Thank you. We have reached the end of our question and answer session. I would now like to turn the floor back over to Russ Trenary for closing remarks.
spk05: Great, thanks so much. Well, I believe the future of Outlook Therapeutics has never been brighter. And 2024 has already proven to be a pivotal year for the company. To summarize, in Europe, the second largest market for wet AMD, we received a positive CMP opinion already and expect potential approval this quarter. This sets the stage for our first commercial launch expected in the first quarter of calendar 2025. In the United States, we reached agreement with the FDA on a path to potential approval and are targeting resubmission of our VLA this calendar year. Assuming cash exercise of the warrants from our recent pipe financing, we expect to be funded through key anticipated milestones, potentially realizing our mission of bringing the first approved ophthalmic formulation of Bevacizumab to patients with retina disease. We look forward to continued progress and the opportunity to bring an enhanced level of care to the retina anti-VEGF space. Thanks for joining us today.
spk10: Thank you. This does conclude today's teleconference. We appreciate your participation. You may disconnect your lines at this time. Enjoy the rest of your day.
Disclaimer